We performed 858 two-dimensional ͑2D͒ patient-specific intensity modulated radiotherapy verifications over a period of 18 months. Multifield, composite treatment plans were measured in phantom using calibrated Kodak EDR2 film and compared with the calculated dose extracted from two treatment planning systems. This research summarizes our findings using the normalized agreement test ͑NAT͒ index and the percent of pixels failing the gamma index as metrics to represent the agreement between measured and computed dose distributions. An in-house dose comparison software package was used to register and compare all verifications. We found it was important to use an automatic positioning algorithm to achieve maximum registration accuracy, and that our automatic algorithm agreed well with anticipated results from known phantom geometries. We also measured absolute dose for each case using an ion chamber. Because the computed distributions agreed with ion chamber measurements better than the EDR2 film doses, we normalized EDR2 data to the computed distributions. The distributions of both the NAT indices and the percentage of pixels failing the gamma index were found to be exponential distributions. We continue to use both the NAT index and percent of pixels failing gamma with 5 % / 3 mm criteria to evaluate future verifications, as these two metrics were found to be complementary. Our data showed that using 2 % / 2 mm or 3 % / 3 mm criteria produces results similar to those using 5 % / 3 mm criteria. Normalized comparisons that have a NAT index greater than 45 and/or more than 20% of the pixels failing gamma for 5 % / 3 mm criteria represent outliers from our clinical data set and require further analysis. Because our QA verification results were exponentially distributed, rather than a tight grouping of similar results, we continue to perform patient-specific QA in order to identify and correct outliers in our verifications. The data from this work could be useful as a reference for other clinics to indicate anticipated trends in 2D verifications under various conditions.
I. INTRODUCTION
Patient-specific quality assurance ͑QA͒ is commonly performed for intensity-modulated radiotherapy ͑IMRT͒ treatments to ensure proper dose calculation and delivery. [1] [2] [3] [4] [5] [6] [7] For each IMRT plan, we perform an ion chamber measurement in a water phantom and a film measurement in a polystyrene or solid water phantom to verify monitor units ͑MUs͒ and treatment planning calculations. Initially, our clinical practice relied solely on qualitative comparisons of isodose lines to detect discrepancies in the measured and computed distributions. We collected an extensive amount of quantitative twodimensional ͑2D͒ dose comparison data and analyzed it in order to determine appropriate clinical tolerance levels for routine use.
The aim of this research was to analyze the dosimetric results of our patient-specific film QA. This included determining the overall agreement between the measured and computed distributions, determining the frequency and cause of outliers, analyzing the effect of using different dose and distance criteria, and assessing the effect of normalizing measured distributions to computed distributions. Data were analyzed using both normalized and unnormalized film doses to evaluate the accuracy of film measurements as relative and absolute doses, respectively. While earlier publications have generally focused on presenting multidimensional results from a small number of verifications, [8] [9] [10] [11] we examined 858 verifications performed over an 18 month time period. Using single-valued parameters to represent the overall agreement of each verification simplified these analyses. The data from this work could be useful for setting clinical tolerances and anticipating potential variations in 2D verification data for clinics with lower patient loads.
II. METHODS AND MATERIALS
An in-house dose comparison program was developed to perform 2D IMRT verifications and to catalog all results. 12 The software, DOSELAB, was written in the MATLAB programming language and used to investigate multiple dose com-parison parameters. All measurements, including those at satellite facilities, were performed with extended dose range ͑EDR2͒ film ͑Eastman Kodak Company, Rochester, NY͒ processed with a Kodak RP X-Omat Model M6B film processor, scanned with a VXR-16 Dosimetry Pro CCD film scanner ͑VIDAR Systems Corporation, Herndon, VA͒ at 71.25 dots per inch ͑dpi͒, and converted from optical density ͑OD͒ to dose distributions using DOSELAB. All treatments were delivered with Clinac 2100 linear accelerators ͑Varian Medical Systems, Inc., Palo Alto, CA͒, identified as M1 through M7, that had matched beam parameters and were equipped with either Varian Millennium 80 or Varian Millennium 120 multileaf collimators ͑MLCs͒. All deliveries were performed with MLCs operating in the step-and-shoot mode. This report summarizes the 858 IMRT film verifications that were performed between November 2002 ͑DOSELAB's clinical implementation͒ and April 2004. Approximately 25 verifications measured two separate planes of a single patient's treatment.
In January 2004, we began requiring at least 1 h between the exposure and processing of EDR2 film in order to minimize the processing time delay effect. 13 Prior to that time, both calibration and QA films were processed at arbitrary times after exposure. If EDR2 film is processed immediately after exposure, its OD can be 4%-6% lower than EDR2 film that is processed several hours after exposure to the same dose. Therefore, short time delays can lead to ODs on calibration films not corresponding to the same doses as the same ODs on patient QA films. However, the time delay effect would appear only if either the calibration film or patient QA films, but not both, were processed less than an hour after exposure.
Treatment plans were designed using CORVUS version 4 or 5 ͑North American Scientific, Chatsworth, CA͒ or PINNACLE 3 version 6.2b ͑Philips Radiation Oncology Systems, Madison WI͒ treatment planning software ͑TPS͒. The clinical treatment fields were used for film measurements, except that MUs were scaled upwards by the respective TPS to produce maximum doses of 200-300 cGy to better match EDR2's usable OD range. Due to the rounded-leaf end design of the Varian MLC, the light field is slightly smaller than the radiation field. In CORVUS, a single value for the offset between the edges of the light and radiation fields is entered in the beam model specifications. A MLC light/ radiation field offset of 0.2 mm was used for all plans reported in this research. This value was determined by visually inspecting the dose uniformity of abutting 2 cm strips delivered to film. We have since analyzed this parameter with other, more quantitative tests and determined that a value of 0.4-0.7 mm may be more appropriate, the precise value depending on the dose methodology used by the treatment planning system. If this value were changed in our CORVUS treatment plans, agreement between calculated and measured distributions should improve, resulting in slightly lower NAT indices and fewer areas failing the gamma criterion. Such an offset adjustment is not possible in PINNACLE 3 6.2b. The "Hybrid plan" and "SniffToTiff" features of COR-VUS were used to calculate dose to the film phantoms and extract TIF images of the computed dose. This was accomplished in PINNACLE by using its "Copy to phantom" and "Planar dose" features.
Transverse plane film measurements of the composite dose distribution were performed for patient IMRT plans. Three different phantoms that hold film in a plane parallel to the beam's central axis were used. Computed tomography scans were performed for all phantoms. One phantom is commercially available from North American Scientific. It is 16.5ϫ 19.5ϫ 16.5 cm 3 in size, constructed with high impact polystyrene, holds bare film cut into 5in.ϫ 5.5in. pieces, and is used for treatments that have small planning target volumes ͑PTVs͒. Very little area outside the PTV is measured due to the small size of the film used. Proper film compression is ensured by tightening plastic screws that apply pressure to the film inside the phantom. For cases with larger PTV areas, an in-house designed 40ϫ 40ϫ 16 cm 3 polystyrene phantom with three internal fiducial markers that pierce the film was used to house 14in.ϫ 17in. EDR2 film in its original jacket. Film compression is controlled with Velcro straps on either side of the phantom. The excess length of film beyond the height of the phantom is allowed to protrude from the top surface. Finally, a solid water phantom that holds full 8in.ϫ 10in. sheets of bare film with three fiducial pressure points was used for IMRT verifications performed at a satellite facility. Dose calculations were based on the CT images and included heterogeneity corrections for all phantoms.
Film calibrations were performed for each QA session using an eight dose level calibration technique 14 to convert measured ODs to absolute dose. Film calibrations were performed in a solid water phantom with the film perpendicular to the beam axis. We also used a CC04 ion chamber ͑Scan-ditronix Wellhofer North America, Bartlett, TN͒ to measure absolute doses in a separate custom water phantom for all IMRT plans. Because our calculated doses in the PTV have a historically good agreement with our ion chamber measurements, 4 we used the computed doses to determine individual normalization factors for each of the measured film distributions. These factors were the average ratio of computed dose to film dose in the PTV region. All pixels in each film dose distribution were multiplied by their respective normalization factor to obtain a normalized measured distribution. We developed a normalization routine that automatically selects the film regions that correspond to the locations usually measured by the ion chamber. The routine finds the average ratio of calculated-to-measured dose for all pixels with computed doses of 80%-95% of the maximum dose in the central area of the registered images. The normalization region was geometrically constrained to avoid including hot spots that are sometimes found at the edge of the phantom or in small beam overlap areas. While the normalization routine only used the central portion of the dose distribution, the film analyses were performed over the entire dose distribution. With this normalization applied, the film results were verifying relative doses rather than absolute doses.
A. Positioning verification
DOSELAB was used to geometrically register the measured and computed dose distributions. This program uses bilinear interpolation to downsample the measured image to the same spatial resolution as the TPS image, which is generally 0.5-1.0 mm/ pixel for CORVUS distributions and 1.0 mm/ pixel for PINNACLE distributions. The user then corrects for rotation of the scanned film image by clicking two fiducial points on the large phantoms or two points on the bottom edge of the film for the small polystyrene phantom. An alignment algorithm that uses a 2D normalized crosscorrelation calculation finds the x-axis and y-axis translations that result in the best match between the computed and measured images. This automatic alignment result is accurate to within 1 pixel ͑0.5-1.0 mm͒. It is difficult for manual registration with fiducials to achieve this level of accuracy for routine measurements due to small errors in phantom positioning, fiducial point marking, and subsequent fiducial point selection. To verify that the phantom was positioned properly and that the algorithm did not produce an unexpected result, the coordinates of the film within the phantom as calculated with the alignment algorithm ͑POS͒ are compared to the expected coordinates calculated from the known geometry of the QA phantom ͑POS exp ͒. The x and y offsets are computed using the formula Offset= POS − POS exp . If either offset is greater than 3 mm, the user is asked to perform a manual alignment to verify that the phantom was positioned correctly and that the automatic registration algorithm worked properly.
B. Dose verification trends
In our clinical practice, physicists initially evaluated film dosimetry results by considering the normalization factor and by evaluating a printout showing computed isodose lines overlaid on measured ones. Only 2 of the 858 verifications were flagged as abnormal by viewing isodose lines. In both cases, the computed dose distribution was incorrectly extracted from the treatment planning system. The other dose comparison parameters presented were initially calculated only for research, but are now also considered when evaluating clinical comparisons.
Both the normalized agreement test ͑NAT͒ index 12 and the percent of pixels that fail the gamma index 15 ͑have a gamma value greater than one for the chosen dose and distance criteria͒ were computed for all verifications using both the normalized and unnormalized film distributions. Local percent differences ͑absolute dose difference divided by computed dose at each pixel͒ were used in NAT calculations, whereas relative percent differences ͑absolute dose difference divided by the maximum computed dose͒ were used to find the percent of pixels failing the gamma index. The NAT index was calculated by first finding the 2D distribution of gamma indices using the measured image as the reference distribution and the computed image as the evaluated distribution. To avoid the small areas with large disagreements that occur at fiducial markers on the measured distribution from artificially inflating the NAT index, gamma index values greater than 5 were truncated to a value of 5. Values were then reduced by one and multiplied by 100 to convert to percentage. Negative values were set to zero. For pixels outside the PTV ͑defined by having a computed dose lower than 70% of the maximum dose͒ that had measured doses less than computed doses, the gamma values were set to zero for the NAT calculation only, as they would likely not have an adverse effect on the patient's treatment. Cold regions were not treated differently for gamma index calculations. The 2D matrix of gamma values was weighted by dose by multiplying each value by the maximum of the computed or measured dose divided by the global maximum dose. To compute the NAT index, the average value of this 2D matrix was computed and scaled by the average dose weighting of the entire verification.
A NAT index of 0 indicates all pixels pass the NAT criteria ͑all pixels pass either the dose or distance criteria or are in cold areas outside the PTV͒, and larger values indicate poorer agreement between the measured and computed distributions. The NAT index was weighted by dose and the amount each pixel fails the given criteria, but these weightings were not used in finding the percent of pixels that fail the gamma index. Note that using gamma index computations to compute the NAT index will produce smaller values than using the deviations from dose and distance criteria, as was performed in the original manuscript. 12 The percent of pixels failing the gamma index was calculated without weighting pixels by dose, ignoring cold areas outside the PTV, or any of the other modifications used in calculating NAT indices.
Analysis of variance ͑ANOVA͒ tests 16 were performed to determine whether the distribution of NAT indices, percentage of pixels failing the gamma index, and film normalization statistically differed with various treatment parameters. Differences due to QA phantom, beam energy, TPS, QA machine, treatment site, and QA date were investigated. As our clinical data set was not sufficiently extensive to analyze all interactions of all parameters, the data sets used to analyze variations were truncated. For example, the data set was restricted to verifications planned with CORVUS using 6 MV beams to test the variations among different QA phantoms. These subsets were chosen to minimize confounding factors while still having a sufficient number of verifications in each subset to show statistical significance. All ANOVA tests were performed using the normalized data set. The Tukey honestly significant difference criterion 16 was used to generate confidence intervals for an alpha value of 0.02, meaning that differences between groups with p-values less than 0.02 were considered significant. Only one-way ANOVA tests were performed; thus no interactions between different parameters were analyzed. All comparisons were also performed using a Kruskal-Wallis nonparametric test. 16 Finally, the ratio of film dose to computed dose was calculated for several different computed dose ranges. These ratios were used to determine whether there were any dosedependent trends in the data set. The average ratio of computed to measured dose was found for computed dose ranges between 0% and 100% in 10% steps. These results were grouped by QA phantom. Unlike the clinical normalization algorithm, no geometric constraint was used when calculating these ratios.
C. Variation with dose/distance criteria and normalization
All plans were evaluated with and without normalizing the film distribution to the computed distribution. Unless stated otherwise, 5 % / 3 mm dose and distance criteria were used in calculating scalar dose comparison parameters. All plans were also evaluated with 2 % / 2 mm, 3 % / 3 mm, and 10% / 5 mm criteria to assess the effect of using other commonly -used criteria.
III. RESULTS
The distribution of the 858 film verifications by treatment sites, beam energy, TPS, and QA phantom is shown in Table  I . This distribution reflects the mixture observed in clinical practice during the time period. Thus, there were relatively few PINNACLE plans and the majority of 18 MV treatments were prostate cases. The solid water phantom was used exclusively for verifications at a satellite location with a lower patient load than at the main campus. The small polystyrene phantom was only used to verify plans with small PTVs, which were typically prostate cases. The use of retrospective data rather than a completely balanced design limits the statistical analyses performed to relatively straightforward comparisons excluding complex multiway ANOVA tests, but permits comparisons of the most common clinical practices.
A. Positioning verification
The distributions of the phantom position offsets are displayed in Fig. 1 . Both the x-and y-offset distributions are approximately Gaussian. The shifts from the expected positions can be attributed to uncertainty in phantom positioning and inaccuracies in selecting the registration fiducial in the measured dose distribution. The x offsets have a systematic error of about 1 mm ͑equal to about 1 pixel in most verifications͒. The positioning algorithm worked well for all verifications except a few mesothelioma distributions, which have PTVs that generally encompass most of the film. The large areas of uniform dose in these mesothelioma PTVs resulted in 2 -8 mm errors in the cross-correlation calculation and the distributions were manually registered.
FIG. 1. Histograms of ͑a͒ x offsets and ͑b͒ y offsets. These offsets are the differences between the shifts computed by the automatic positioning algorithm and the expected shifts computed from known phantom geometries. Figure 2 shows histograms of the film normalization values. The film normalization's overall average shows a 2% difference from the computed PTV doses and a 4.8% standard deviation. The large solid water phantom's normalizations were significantly different from the others ͓Fig. 2͑b͔͒, but its sample size was relatively small ͑n =48͒. PINNACLE normalizations were significantly less than those planned in CORVUS. However, our ion chamber data indicate that there is no systematic difference between measured and computed PTV doses and that there is a much tighter 1.7% standard deviation. 4 Furthermore, the outliers in our film normalizations did not correlate to the outliers in the corresponding ion chamber QA results, perhaps because the film normalization calculation considers the entire PTV area while ion chamber results only verify a single point. This was true both before and after we began waiting an hour before processing QA and calibration films to account for the processing time delay effect. Figure 3 contains histograms of normalized and unnormalized NAT indices and percent of pixels failing gamma. Normalizing the measured distributions resulted in lower NAT indices as well as fewer pixels failing gamma. It also reduced the standard deviations of both distributions. Both
B. Dose verification trends
One-way ANOVA results are shown in Fig. 4 and the main results are summarized in Table II . ANOVA tests are designed to be used with Gaussian distributions, but the distributions of the NAT index and percent of pixels failing the gamma index were exponential distributions. Because the qualitative results of the Kruskal-Wallis test agreed with the ANOVA results it was felt that the ANOVA test was sufficiently robust. The NAT index and percent of pixels failing gamma both indicate better agreement for the small polystyrene phantom measurements than the large polystyrene phantom measurements. The small phantom measurements had better agreement because its film is only large enough to measure PTV regions. The solid water phantom measurements had an average film normalization about 10% lower than the two polystyrene phantoms and NAT indices that were significantly lower than those of the large polystyrene phantom. There were no statistically significant differences for the two beam energies or among the seven different machines used for IMRT QA.
The difference in CORVUS and PINNACLE verifications was significant for all three metrics-NAT indices, pixels failing gamma, and film normalization. CORVUS verifications had lower NAT indices ͑i.e., "better" agreement͒, but a higher number of pixels failing gamma ͑i.e., "worse" agreement͒. This means that more pixels in PINNACLE verifications pass the 5 % / 3 mm criteria, but the failing areas have larger differences than the areas that fail CORVUS verifications. This agrees with qualitative results of viewing full 2D comparison images. PINNACLE verifications always have excellent agreement in the overall shapes, peaks, and valleys of the measured and computed distributions. However, most comparisons have thin hot streaks because the curved end of the MLC leaf is not modeled, and it is common for areas outside the PTV to have higher measured doses than computed doses. An in-house test of one comparison revealed that these hot streaks were reduced when the MLC files were manually altered such that each MLC leaf opening was reduced by a total of 1.2 mm, similar to the method CORVUS uses to account for the light/radiation field offset of roundedleaf MLCs. CORVUS verifications sometimes show poor qualitative agreement in areas outside the PTV, especially near the phantom edges, leading to a larger number of pixels failing criteria than PINNACLE verifications. The average film normalization was 5% lower for PINNACLE verifications than it was for CORVUS verifications.
The differences among treatment sites are minor when restricted to the CORVUS, large polystyrene phantom, 6 MV data set. However, the treatment site can often dictate the beam energy, QA phantom, and sometimes QA machine used for planning and verification. ANOVA tests performed with the full data set indicated that there were more statistically significant variations in treatment sites due to the interactions of these other parameters. The "Other" category is primarily composed of thoracic and central nervous system treatments. Table II. The NAT index and film normalization trends with time are shown in Fig. 5 . The NAT index shows a slight trend upward over time ͓Fig. 5͑a͔͒. We attribute this increase in part to the gradual adoption of IMRT for many more disease sites, some of which show higher NAT index values ͑Fig. 4͒. Prior to January 2004, the average film normalization was 1.031± 0.047 ͑n = 293͒. After we instituted a minimum time delay of 1 h before processing, the average film normalization was 0.993± 0.041 ͑n =24͒. Although the monthly variations in film normalization may not be significant, the effect due to the time delay was statistically significant ͑p = 0.007, student's t-test͒. Although the average film normalization was closer to its ideal value of one, its standard deviation only slightly decreased.
The ratio of measured to computed dose as a function of dose is shown in Fig. 6 for all three phantoms. The large polystyrene phantom has an average ratio slightly over 1.0 for doses above 20%, although the standard deviation is larger for the lower doses. The ratio is artificially high for doses above 90% due to hot spots in overlapping beam areas near the edges of the phantom. This effect is the reason we added the geometry constraint to our autonormalization program, although it is mainly observed for measurements in our large polystyrene phantom. For very low dose areas ͑Ͻ20% ͒, an average ratio greater than 1.25 indicates that the film measurement is typically much lower than the computed doses. This can also be seen for doses less than 50% in the small polystyrene phantom. Because the film rarely measures doses in this range in the small polystyrene phantom, these data are not a reliable indicator of its low dose agreement. The average ratio stabilized at values slightly greater than 1.0 for doses above 50%. The solid water phantom's average ratio is slightly lower than 1.0 after 80%, however from 20% to 80% its average starts at approximately 1.1 and slowly decreases. As with the large polystyrene phantom, doses less than 20% resulted in average ratios greater than 1.0. While this test is useful in determining whether low-dose areas generally have a different level of agreement than high-dose areas, the results include a substantial number of ratios calculated in high-gradient areas. It is possible that ratios with computed doses outside the PTV ͑less than 70%-80%͒ represent spatial shifts more than the average dose differences. Figure 7 plots the percent of pixels failing gamma against the NAT index for all verifications. These two metrics have a weak linear correlation, and individual measurements can differ substantially. For example, the verification at point A has a low NAT index due to an error in extracting its computed dose that led to extremely cold areas outside the PTV. FIG. 3 . Histograms of the normalized agreement test ͑NAT͒ index for ͑a͒ normalized and ͑b͒ unnormalized data sets, as well as the percent of pixels that fail the gamma index for ͑c͒ normalized and ͑d͒ unnormalized data. All 858 patients are included in these data sets and 5 % / 3 mm criteria were used to compute the parameters.
Because the NAT index calculation ignores cold areas outside the PTV, it gives significantly different results than the percent of pixels failing gamma. Figure 6 demonstrates that the verification agreement has a slight dose dependence in our results. The other verifications, which are more typical of clinically observed verifications, differ in expected manners. The percent of pixels that fail gamma is low and the NAT index is high for comparisons that have a few small areas that fail the criteria by large amounts. The percent of pixels that fail gamma is high and the NAT index is low for comparisons in which many areas fail the criteria by small amounts. Because the parameters are computed similarly, but have different weighting, they emphasize different types of discrepancies.
C. Variation with dose/distance criteria and normalization
Both the NAT index and the percent of pixels that fail gamma were calculated with different dose and distance criteria, as shown in Fig. 8 . The 5 % / 3 mm and 2 % / 2 mm criteria span the range widely used in the clinical, and the 10% / 5 mm criteria were included to highlight verifications that demonstrated significant disagreement. The NAT index results for 5 % / 3 mm and 2 % / 2 mm were highly correlated, meaning that tightening the criteria will result in higher absolute values but is unlikely to significantly change the ranks of the individual comparisons. Therefore, changing the crite- FIG. 4 . Bar charts showing the variation of NAT indices and percent of pixels failing gamma with ͑a͒ quality assurance phantom, ͑b͒ beam energy, ͑c͒ treatment planning system, ͑d͒ quality assurance machine, and ͑e͒ treatment site. Error bars indicate ANOVA uncertainty levels corresponding to an alpha of 0.02. The data sets used to generate these figures are specified in Table II. ria would change the values of the NAT index, but the same plans would likely pass clinical criteria. On the other hand, because the percent of points that fail gamma is not as well correlated for 5 % / 3 mm as compared to 2 % / 2 mm or 10% / 5 mm, changing the criteria may change which plans pass a given level of acceptability. The 10% / 5 mm results were less correlated to the 5 % / 3 mm results for both the NAT index and the percent of pixels failing gamma. While not shown, data computed using 3 % / 3 mm criteria had second-order polynomial R 2 values of 0.98 and 0.84 for 5 % / 3 mm NAT index and gamma index results, respectively, indicating slightly stronger correlations than 2 % / 2 mm criteria. Figure 9 demonstrates that calculating NAT indices and percent of pixels failing gamma for normalized and unnormalized distributions does not yield highly correlated results. Therefore, the accuracy of relative film measurements is not well correlated to its accuracy as an absolute dosimeter. 
IV. DISCUSSION

A. Positioning verification
As part of our film verifications, we perform offset calculations to determine the setup accuracy of our QA measurements. The standard deviations in the x and y offsets show that the positioning precision was very high, as approximately 95% of measurements were within 2.5 mm of their expected values. Our autopositioning algorithm registers the images to the nearest pixel, thus removing setup and measurement errors from our analyzed data. Offsets from the expected position are unavoidable-phantom positioning can be 1 -2 mm off and it is easy for the user to miss the center of the alignment fiducial by 1 or 2 pixels-so that a standard deviation of 1.2-1.3 mm is quite reasonable. The systematic 1 mm error in the x offsets was most likely due to an error in entering the expected x positions for 1 or more of the phantoms. The user must estimate the distance from the edge of the CT scan to the edge of the phantom and then add in phantom coordinates to obtain the total offset. Misjudging the expected offset by one pixel for either the CT scan or film phantom edge would result in a 1 mm systematic offset difference for all measurements. The autopositioning algorithm reduces the time needed to perform film analysis and can identify serious alignment problems ͑Ͼ5 mm͒. It is also able to align the two images with 1 mm or better precision, which cannot be achieved by users manually identifying fi- ducial markers on the computer screen. The use of an alignment algorithm is essential to correct for our 1 -2 mm daily positioning inaccuracies, as it is possible for the positioning error to be nearly all of our 3 mm distance to agreement criteria. If another user or clinic makes measurements and does not use an automatic positioning algorithm to correct the data's slight positioning variations, their NAT and gamma results will differ from those that we present.
B. Dose verification trends
We analyzed our results as functions of QA phantom, beam energy, treatment planning system, linear accelerator, treatment site, date, and dose range in order to identify trends and potential problems in our QA dosimetry. This analysis can be used to set different passing thresholds based on the treatment and verification conditions. For example, significantly different results were obtained for the QA different phantoms so that different acceptable NAT index and gamma index values can be set for each one. We can also use the results to monitor accelerator performance and determine if one may need repair. If comparisons get worse over time, we can attempt to determine the cause by investigating changes that occurred in the same time period. The exhaustive analysis of these first 18 months of QA using EDR2 film provided a baseline for future performance and showed which of these components have large effects on QA results.
There were several common causes of high ͑Ͼ45͒ NAT indexes and high ͑Ͼ20% ͒ percent of pixels failing gamma for normalized distributions. The processor left roller marks and splotches on about ten films that resulted in areas with large disagreement, fiducial markers on the film produced abnormally high dose disturbances in approximately five verifications, the computed dose was not correctly extracted for two cases, some plans were very complicated and the measurement did not match well with the calculation in all areas, and there were plans that had measured doses higher than were computed for nearly all areas outside the PTV. While quantitative comparisons can be very useful, slight measurement inaccuracies, such as processor glitches, had a higher impact on quantitative results than qualitative isodose line comparisons. The overall systematic film normalization difference and large variations ͓Fig. 2͑a͔͒ limit the usefulness of EDR2 film as an absolute dosimeter. They may be the result of inaccurate film scanner performance, different calibration and patient film geometries, inconsistent EDR2 OD response or the fact that a large 2D area of the PTV is being evaluated for each patient. The 2% difference in 6 and 18 MV normalizations is not due to film calibration errors. We perform calibrations at the same energy as measurements and EDR2 sensitometric curves for 6 and 18 MV show little energy dependence. 14, 17, 18 It is possible that correcting for the processing time delay effect will resolve the systematic discrepancy in film normalization, although accounting for this effect only slightly decreased the large standard deviation of the film normalization data. More data are needed that do not include errors due to the processing time delay effect to assess EDR2 film's usefulness as an absolute dosimeter for IMRT verifications.
It is not clear why the solid water phantom shows better agreement than the large polystyrene phantom, as the film sizes are similar. This could be due to a difference in treatment planning system beam models between the main campus and satellite location. It is also possible that differences in phantom composition and size could produce different scatter spectra at depth, changing the film response slightly. 19 As solid water is a better water substitute than polystyrene, the polystyrene phantom must also rely more heavily on heterogeneity corrections. All of these phantoms were designed to perform measurements that were sufficiently accurate for isodose line comparisons. Thus, it is possible that some dosimetric discrepancies are caused by phantom design that is insufficiently accurate for rigorous quantitative 2D analyses. The high average film normalization for low dose regions in both of the large phantoms could result from a systematic TPS low-dose calculation inaccuracy, but it more likely can be attributed to the fact that these areas occur almost exclusively in high-gradient regions and are very sensitive to slight positional changes. Because only the solid water phantom showed a difference in the normalization as a function of dose, it could be assumed that this is a phantom-specific result rather than a systematic TPS dose calculation inaccuracy.
The normalization differences between CORVUS and PIN-NACLE may be due to their different MLC sequencing algorithms. Pinnacle plans tend to use fewer segments and have larger MLC openings than CORVUS plans, which could potentially alter the amount of low-energy scatter that can cause overresponse in silver halide films. Better modeling of the MLC shape in PINNACLE should result in lower average PTV film doses without significantly changing ion chamber readings.
Although there were a few statistically significant differences among the various linear accelerators used for patientspecific QA, the differences were minor and may represent higher order interactions or interactions of other parameters that were not removed in the truncated data set. Either way, these minor dissimilarities are not likely to be significant in the overall quality of patient care. It is interesting to note that two of the most dissimilar treatment sites, mesothelioma and prostate, had nearly identical NAT indices and film normalizations. This result gives us confidence that the accuracy of our planning systems does not systematically diminish with large, complex plans.
The percent of pixels failing gamma was less sensitive to differences in the groups shown in Table II than the NAT index. This could result from the inherently reduced sensitivity of a metric that is not weighted by the amount pixels fail the criteria, or it could more accurately represent that there were no significant differences in these groups. These two metrics complemented each other nicely, in part because they are largely uncorrelated. One can look at the percent of pixels that fail gamma to gain an understanding of the portion of the verification that fails criteria, whereas the NAT index identifies the average deviation from the criteria.
C. Variation with dose/distance criteria and normalization
We were uncertain as to which dose and distance criteria to use when we began performing quantitative 2D dosimetry. Because one of the main goals was to use scalar metrics to create pass/fail criteria, we were concerned about whether the choice of dose and distance criteria and/or scalar metric͑s͒ would have a large effect on which plans were deemed to pass the given standard. Therefore, we examined the quantitative effect of using different dose and distance criteria as well as using NAT indices and percent of pixels failing gamma by determining how well the results of using different criteria and metrics were correlated.
There were no significant outliers in any of the distributions that would indicate that the use of 5 % / 3 mm, 3 % / 3 mm, or 2 % / 2 mm criteria would better flag clinically significant problems. Using 10% / 5 mm criteria significantly reduced the sensitivity of the percent of pixels that fail gamma and is not recommended for clinical use. Changing the criteria may lead to more correlated results for the NAT index due to its use of local percent differences rather than the gamma index's use of relative percent differences, as small changes in a relative percent difference can more easily alter the number of pixels failing criteria than small changes in a local percent difference. The reduced correlation between normalized and unnormalized data sets indicates that the decision of whether to perform normalization could significantly affect which patients are flagged as outliers in the clinical data set. Since the normalizations of our ion chamber do not match our EDR2 film normalizations, we believe that normalizing the measurements to the computed distribution yields more accurate results. If we chose not to normalize, the single-valued parameters would flag many verifications as having large discrepancies due solely to inconsistencies in the absolute dose response of EDR2 film.
While one of the original goals of this research was to identify clinical tolerance limits for 2D IMRT verifications, there was no clear dividing line between normal verifications and outliers for either the NAT index or percent of pixels failing gamma. However, normalized comparisons with NAT indices larger than 45 and/or more than 20% of their pixels failing gamma for 5 % / 3 mm criteria warrant further investigation. These criteria only identify verifications that are statistical outliers in our data set and do not represent possible biological effects of dose discrepancies. These limits will change with different measurement techniques and are not recommended as universal acceptance standards, but are useful for comparison to individual clinics' results. Singlevalued parameters are excellent tools to allow clinics to analyze trends and identify anomalies in large amounts of data, but they do not replace the invaluable information that can be gathered by viewing full 2D dose comparison images, such as dose differences and interactive profiles.
V. CONCLUSIONS
We retrospectively analyzed 858 2D film verifications using many methods intended to clearly identify outliers in individual patient's verifications as well as trends in the full data set. Based on these results, we selected the NAT index and the percent of pixels failing gamma as our primary metrics and set preliminary tolerance limits ͑NAT indices above 45 or more than 20% of pixels failing gamma, both for 5 % / 3 mm criteria͒ for identifying verification outliers. These outliers may be the result of "a number of steps" in the inverse planning process not being "adequately rigorous" 5 and might not be amenable to remediation by end users. While tolerance levels are institution and measurement technique dependent, our methodology can be used by clinics with lower patient loads to anticipate trends and potential causes of outliers. By studying future outliers in detail ͑per-forming single beam verifications, multiple ion chamber measurements, repeating the QA measurements, etc.͒, we expect to determine their causes and implement solutions that will result in improved QA.
Analyzing these data led us to several conclusions about our patient-specific IMRT QA process. We found that it was important to use an automatic positioning algorithm to achieve maximum registration accuracy and that our automatic algorithm agreed well with expected results. Our EDR2 film absolute dose data for PTV regions has a much larger standard deviation than previous ion chamber data, so we continue to normalize EDR2 data to the computed distribution. Our verification results were not dependent upon beam energy, linear accelerator, or treatment site, but were dependent upon the selection of QA phantom and treatment planning system. We continue to use both the NAT index and percent of pixels failing gamma with 5 % / 3 mm criteria to evaluate verifications, as the two metrics were found to be complementary. Our data showed that 2 % / 2 mm or 3 % / 3 mm criteria produce results fairly correlated to those using 5 % 3 mm criteria. Because our QA verification results were exponentially distributed, rather than a tight grouping of similar results, we will perform patient-specific QA in order to identify and correct outliers in our verifications.
